この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2016/6/81 分で読めます
Determination of Regulatory Review Period for Purposes of Patent Extension; ALPROLIX
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) has determined the regulatory review period for ALPROLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →